Rigel Receives Positive CHMP Opinion for Fostamatinib Disodium Hexahydrate for Adult Patients with Chronic Immune Thrombocytopenia (ITP) in Europe

SOUTH SAN FRANCISCO, Calif., Nov. 15, 2019 -- (Healthcare Sales & Marketing Network) -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Med... Biopharmaceuticals, Regulatory Rigel Pharmaceuticals, fostamatinib, immune thrombocytopenia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news